1. Scrip

With Two BCMA-Targeting Myeloma Treatments, Which Should Be First Choice?

Experts Weigh In On Positioning BMS/Bluebird’s Abecma And GSK’s Blenrep

 
• By Alaric DeArment

Market Snapshot: GSK's Blenrep and BMS's Abecma are the first of many drugs for the late-line setting. In many cases, the CAR-T may be the first choice, but some patients are unable to handle it or risk progressing while awaiting treatment.

Open Book Of prostate multiple myeloma, Conceptual Image - Image
With two BCMA-targeting myeloma therapies available, the question now is how to position them in treatment • Source: Shutterstock

With two BCMA-targeting therapies now approved for multiple myeloma – GlaxoSmithKline plc’s antibody-drug conjugate Blenrep (belantamab mafodotin-blml) and bluebird bio/Bristol Myers Squibb Company’s CAR-T therapy Abecma (idecabtagene vicleucel) – the question becomes how their differences in efficacy, toxicity and logistics determine which will be the first option for patients. That will be especially pertinent as more anti-BCMA therapies become available in the coming years.

In the first quarter of 2021, Blenrep had sales of £21m ($29m), the London-based drug maker announced 28 April

More from Market Snapshot

More from Scrip

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

 
• By Andy Smith

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.